How CluePoints Enabled Pfizer's 'Hyperspeed' Vaccine Development
Leveraging Risk-Based Quality Management to Facilitate Early Risk Detection
How CluePoints Detected Fraudulent Reporting of Investigational Product Administration from Patient Diary Data
Using CluePoints to Detect Anomalies in Electronic Patient-Reported Outcomes
Using CluePoints to Identify Severe Propagation in Vital Sign Measurements
Using CluePoints to Identify Fraud Due to the Fabrication of Patient Diaries
Using CluePoints to Detect Miscalibrated Equipment in a Clinical Trial
The Value of the CluePoints Solution in Identifying Under-reported Adverse Effects in a Clinical Trial
Using CluePoints to Reveal Protocol Deviations in Patient Selection
Conclusions from Executive Roundtable on Response to ICH E6 (R2)
Implementing a Scalable Risk-Based Monitoring Strategy
Sponsor Responses to the ICH E6 Revisions
The Principles of Central Statistical Monitoring
Tufts Center for the Study of Drug Development Impact Report: Analysis & Insight Into Critical Drug Development Issues
Statistical Monitoring of Data Quality and Consistency in the Stomach Cancer Adjuvant Multi-Institutional Trial Group Trial
Data-Driven Risk Identification in Phase III Clinical Trials Using Central Statistical Monitoring
The Role of Biostatistics in the Prevention, Detection, and Treatment of Fraud in Clinical Trials
A Statistical Approach to Central Monitoring of Data Quality in Clinical Trials
Centralized Statistical Monitoring as a Way to Improve the Quality of Clinical Data
Linear Mixed-Effects Models for Central Statistical Monitoring of Multicenter Clinical Trials
Use of the Beta-Binomial Model for Central Statistical Monitoring of Multicenter Clinical Trials
A Hercule Poirot of Clinical Research
Ensuring Trial Validity by Data Quality Assurance and Diversification of Monitoring Methods
Fraud in Clinical Trials: Complex Problems, Simple Solutions?
Impact of On-Site Initiation Visits on Patient Recruitment and Data Quality in a Randomized Trial of Adjuvant Chemotherapy for Breast Cancer
Data Fraud in Clinical Trials
Applied Clinical Trials: Ukraine War's Impact on Clinical Research: Evidence from Key Risk Indicators
International Clinical Trials: Women in Pharma 2023 | Growing Leadership and Choosing Your Priorities
Applied Clinical Trials: ICH E6(R3) Ushers in the Risk Based Quality Management Era – But Are We Ready?
Quality Tolerance Limits’ Place in the Quality Management System and Link to the Statistical Trial Design: Case Studies and Recommendations from Early Adopters
OutsourcingPharma: Paving the path for risk-based quality management and sharing insight at DIA Global
OutsourcingPharma: Interview: How CluePoints is making clinical trials 'safer, streamlined and more efficient'
How ICH E6 (R2) Provides a Win/Win/Win through Risk-Based Study Execution
From RBM to RBx: The Keys to Successful Adoption and Implementation
What Does Risk Mean?
Leveraging Intelligent Analytics to Realize the Full Value of RBx and Compliance with ICH E6 (R2)
FDA Offers Further RBM Guidance Stressing Data Quality Oversight
How SMEs Can Achieve Regulatory Compliance Through a Risk-Based Approach
Update on ICH E6 (R2) Guideline for GCP
A Revolutionary Cure for RBM and Centralized Monitoring
The Bigger Picture of the ICH E6 (R2) – Looking Beyond Compliance
ICH E6 (R2) – Miracle Pill for the Clinical R&D Industry
Got a Question?
Whether you’re looking to get started or need support, we’re here to help!
Featured Whitepaper
ICH E6 (R2)
Summary
Paper
Created in conjunction with our peers at TUFTS Center for the Study of Drug Development, this paper provides insights on how companies are responding to ICH E6 (R2) and information on the key themes on adoption.
Featured Webinar
ICH E6 (R2)
Webinar
Series
This recorded webinar covers all of the frequently asked Questions about ICH E6 (R2), Risk-Based Study Execution (RBx) and what’s required from a people, process & technology standpoint.
We're Kind of a Big Deal.
7,000
Platform Users
1,200
Studies De-Risked
100,000
Issues Detected